Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04548401
  4. Details
NCT04548401 Clinical Trial

Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage Clinical Trial

Official title:
Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04548401
Other study ID # aSAH016
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2019
Est. completion date December 31, 2021

Study information
Verified date September 2020
Source Nanjing Medical University
Contact Zhen Yu Jia, MD.
Phone +86 13770918208
Email zhenyu_jia@sina.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Deficits in memory, executive function, and language are common cognitive sequelae of aneurysmal subarachnoid hemorrhage (aSAH). Previous study demonstrated that post-treatment antiplatelet therapy reduced risk for delayed cerebral ischemia caused by aSAH. However, the effect of antiplatelet therapy on cognition after aSAH is unclear. The aim of this study was to assess the effect of antiplatelet therapy on cognition after aSAH.

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date December 31, 2021
Est. primary completion date October 31, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- 1. Patients with SAH in whom the aneurysm was proven by conventional angiography; 2. Baseline Hunt-Hess grade I-III; 3. patients received endovascular treatment

Exclusion Criteria:

- 1. Hunt-Hess grade IV-V; 2. Non-aneurysmal SAH; 3. Dementia in other diseases; 4. Lacking of 6-8 month MoCA evaluation.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Antiplatelet Drug
aspirin and/or clopidogrel or ticagrelor

Locations
Country Name City State
China The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu

Sponsors (1)
Lead Sponsor Collaborator
Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Montreal Cognitive Assessment (MoCA) Test 6-8 months
See also
  Status Clinical Trial Phase
Completed NCT03209830 - Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Not yet recruiting NCT03271697 - Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage Phase 2/Phase 3
Not yet recruiting NCT05483751 - Micro- and Macrovascular Parameters in Delayed Cerebral Ischemia
Recruiting NCT01098890 - Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT00692744 - Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH) N/A
Recruiting NCT05738083 - Machine Learning-based Prediction of Complications, Disability, and Death in Patients With aSAH
Completed NCT03754335 - SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture N/A
Completed NCT06076590 - Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study Phase 4
Recruiting NCT04148105 - Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 4
Recruiting NCT02129413 - Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm N/A
Terminated NCT00487461 - Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT05974111 - COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
Recruiting NCT03706768 - Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06284642 - Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK) Phase 4
Recruiting NCT01773200 - Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage N/A
Completed NCT02026596 - SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage N/A
Recruiting NCT04566991 - Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 2
Not yet recruiting NCT05282836 - Early Hydrogen-Oxygen Gas Mixture Inhalation in Patients With Aneurysmal Subarachnoid Hemorrhage (HOMA) N/A